Ningbo Shifang Pharmaceutical Technology

Shifang Pharma is a biotechnology company headquartered in Ningbo, China, dedicated to the development of innovative protein degradation therapies. The company focuses on the discovery of molecular glue degraders, a modality designed to target proteins previously considered undruggable by traditional small molecules. Utilizing its proprietary discovery platform, Shifang Pharma is building a robust pipeline primarily centered on oncology and immunology indications. Its lead research programs target key proteins such as GSPT1 and members of the Ikaros transcription factor family for the treatment of solid tumors and hematological cancers. Since its inception in 2021, the company has attracted significant investment from leading venture capital firms like HighLight Capital and Matrix Partners China to accelerate its transition to clinical development.